Lixisenatide
ApprovedPeptide
SanofiLixisenatide is a peptide that works as a Glucagon-Like Peptide 1 Receptor Agonist.[2] It is being used across 7 indications, with its most advanced program in Approved.[1]
Lixisenatide is one of 225 small molecule programs targeting Acute Coronary Syndrome. It is currently in Approved.
7
Indications
42
Total Trials
0
Active Trials
224
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Lixisenatide
SanofiApproved
Byetta
AstraZenecaPreclinical
NOVOLIN R
Novo NordiskPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Glargine
Eli LillyPreclinical
Aurlumyn
BBTG International Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Sulfonylureas
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 2 Diabetes19 trials
Show 16 more trials
Type 2 Diabetic Patients5 trials
Type 2 Diabetes Mellitus4 trials
Diabetes Mellitus3 trials
9 more indications
Function1 trial
Lip1 trial
Acute Coronary Syndrome1 trial
Efficacy and Safety1 trial
Gastric Emptying1 trial
Gastroesophageal Reflux1 trial
Parkinson's Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lixisenatide. EMBL-EBI & Wellcome Sanger Institute.
- [4]